Surgery recognized as effective treatment

December 21, 2009

Doha, December 16, 2009 - A first-of-its-kind consensus statement by 50 medical experts from around the world has pronounced surgery to be a legitimate and effective treatment for type 2 diabetes, bringing the procedure a significant step closer to wider use and acceptance.

The report, recently published in the Annals of Surgery, illustrates the findings of the first Diabetes Surgery Summit (DSS), an international conference held at the Catholic University of Rome, Italy, where more than 50 scientific and medical experts agreed on a set of guidelines and definitions to guide the use and study of gastrointestinal surgery to treat type 2 diabetes.

"This is very good news for people in Qatar and other Gulf countries where diabetes continues to be a major health concern," says Bakr Nour, MD, professor of surgery at Weill Cornell Medical College in Qatar and vice chair of surgery at Weill Cornell Medical College in New York. "It is estimated that 15 to 20% of GCC nationals suffer from diabetes, though many may be unaware that they have it. The disease rates continue to rise both in adults and children, and prevalence among Qatari children has doubled in the past 10 years."

"While more study has been recommended, consensus about surgery as an effective treatment for select patients with type 2 diabetes means that many more patients will be considered as candidates for the procedure," says Dr. Nour. "It could mean a dramatic improvement in the quality of life for those patients for whom lifestyle changes and less invasive therapies prove insufficient."

"The recommendations from the DSS are an opportunity to improve access to surgical options supported by sound evidence, while also preventing harm from inappropriate use of unproven procedures," says the consensus paper's lead author Dr. Francesco Rubino, director of the gastrointestinal metabolic surgery program at NewYork-Presbyterian Hospital/Weill Cornell Medical Center and associate professor of surgery at Weill Cornell Medical College.

The article in the Annals of Surgery summarizes the mounting body of evidence showing that bariatric surgery effectively reverses type 2 diabetes in a high proportion of morbidly obese patients, sometimes within weeks or even days, well before the patients have lost a significant amount of body weight.

Currently, bariatric surgery is only available as a treatment for severe obesity, defined as a body mass index of 35 kg/m2 or more, according to National Institutes of Health guidelines established in 1991. The consensus statement acknowledged that the cutoff is arbitrary and not supported by scientific evidence. "With an emphasis on caution and patient safety, the statement boldly advances a revolutionary concept, the legitimacy of gastrointestinal surgery as a dedicated treatment for type 2 diabetes in carefully selected patients," explains Dr. Rubino.

Based on earlier studies and on clinical experience in other countries, Dr. Rubino and his colleagues have found that removing portions of the jejunum or duodenum -- the upper part of the small intestine right below the stomach -- leads to spontaneous improvement or even resolution of diabetes. The same holds true when the surgeon simply inserts a tube in that part of the intestine, allowing food to pass through without coming into contact with the area. These findings suggest that when food normally passes from the stomach into the upper end of the small bowel, it triggers a cascade of hormonal reactions that cause diabetes.

"Prevention will always be the best strategy to approach the global epidemic of diabetes," says Dr. Rubino. "But gastrointestinal surgery promises to be an important addition to the treatments available, and its study may also allow us to understand the disease mechanism in depth. We can only prevent what we truly understand."

Established in partnership with Qatar Foundation, WCMC-Q is part of Weill Cornell Medical College (WCMC), the first US institution to offer its MD degree overseas. WCMC-Q shares the tripartite mission of WCMC: a dedication to excellence in education, patient care, and biomedical research.

WCMC-Q offers an innovative program of pre-medical and medical studies leading to the Cornell University MD degree. Teaching is by Cornell and Weill Cornell faculty, including physicians at Hamad Medical Corporation (HMC) who hold Weill Cornell appointments.

Faculty and staff of WCMC-Q and WCMC are building the research capacity of Qatar in partnership with Qatar Foundation, HMC, the Ministry of Health and other organizations, with a focus on high quality research in genetic and molecular medicine, women's and children's health, gene therapy, and vaccine development.


About Qatar Foundation

Founded in 1995 by decree of His Highness Sheikh Hamad Bin Khalifa Al Thani, Emir of Qatar, Qatar Foundation is a non-profit organization focusing on education, scientific research and community development. Under Qatar Foundation's umbrella are Education City, which comprises elite universities, several academic and training programmes and Qatar Science and Technology Park, which boasts more than 21 world class companies involved in scientific research and development.

Chaired by Her Highness Sheikha Mozah bint Nasser Al Missned, Qatar Foundation also aims to enhance lives through community development initiatives including Doha Debates, Reach out To Asia and Al Jazeera Childrens Channel.

Joint venture partnerships in the areas of design, ICT, telecommunications, policy studies and event management contribute to fulfilling the objectives of Qatar Foundation.


Weill Cornell Medical College-Qatar

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to